How to Get Mounjaro: The Type 2 Diabetes Access Map

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Author: FormBlends Editorial

Key Takeaways

• Mounjaro is FDA-approved only for type 2 diabetes; weight loss is not on the label
• Insurance prior authorization typically requires documented T2D and a metformin trial
• Retail cash-pay runs around $1,100/month; manufacturer savings cards require commercial insurance
• Lilly Cares patient assistance program serves qualifying low-income uninsured patients
• Non-diabetic patients seeking tirzepatide should pursue Zepbound (obesity indication), not off-label Mounjaro

Direct answer

You can get Mounjaro through three main pathways in 2026, all requiring documented type 2 diabetes. Insurance is the most common path, requiring T2D diagnosis (HbA1c 6.5%+), often a metformin trial, and prior authorization. Retail cash-pay at around $1,100 per month is available with a valid prescription but no manufacturer cash-pay direct-to-consumer program exists for Mounjaro. Compounded tirzepatide through 503A pharmacies costs $300-$600 per month with clinician-documented medical necessity. Non-diabetic patients seeking tirzepatide should use Zepbound rather than off-label Mounjaro.

Table of contents

1. The three Mounjaro access paths
2. Insurance pathway in detail
3. Step therapy navigation
4. Cash-pay realities (no LillyDirect for Mounjaro)
5. Lilly Cares patient assistance
6. The compounded tirzepatide alternative
7. Mounjaro vs. Zepbound: which to pursue
8. Combination therapy with other diabetes medications
9. Common access delays
10. Contrary view: should weight-loss access be expanded
11. Decision framework
12. FAQ
13. Sources

The three Mounjaro access paths

Path	Eligibility	Cost	Timeline
Insurance + T2D diagnosis	Documented T2D, often metformin trial	Copay $25-$300/month	1-2 weeks including prior auth
Retail cash-pay	Valid prescription	~$1,100/month	Same day at retail pharmacy
Compounded tirzepatide	Clinician-documented medical necessity	$300-$600/month	3-7 days through 503A pharmacy

There is no LillyDirect program for Mounjaro comparable to the Zepbound Self Pay Journey Program. Patients seeking lower manufacturer-direct pricing would need to pursue Zepbound if their clinical situation supports it (BMI 30+ obesity indication).

Insurance pathway in detail

The on-label insurance route. Steps:

1. Schedule with your primary care provider, endocrinologist, or diabetes educator
2. Get HbA1c drawn at a CLIA-certified lab
3. If HbA1c 6.5%+ confirms type 2 diabetes
4. Provider discusses Mounjaro as part of T2D management plan
5. Provider submits prescription and prior authorization to insurance
6. Insurance reviews documentation and approves/requests more information
7. Prescription routes to your pharmacy
8. Pick up at the pharmacy with copay

Common prior authorization requirements:

• Recent HbA1c result (typically within 90 days, CLIA-certified lab)
• T2D ICD-10 code (E11.x) in clinical documentation
• Documented metformin trial (typically 3+ months) or metformin contraindication
• Sometimes: HbA1c threshold above 7.0% or 7.5%
• Sometimes: prior sulfonylurea or DPP-4 inhibitor trial
• Confirmation of no contraindications

Eli Lilly's manufacturer savings card for Mounjaro can reduce copays for commercial insurance patients to $25-$150 per month depending on plan and eligibility. The card does not apply to Medicare, Medicaid, or other government-funded patients.

Step therapy navigation

Step therapy is the practice of requiring patients to try less expensive medications first before approving higher-cost alternatives. For Mounjaro specifically, common step therapy patterns:

Plan Pattern	Required Steps Before Mounjaro
Pattern A	Metformin (3+ months) → Mounjaro
Pattern B	Metformin → sulfonylurea or DPP-4 inhibitor → GLP-1 class (Ozempic, Trulicity) → Mounjaro
Pattern C	Metformin → SGLT2 inhibitor → Mounjaro
Pattern D	No step therapy after metformin

Navigating step therapy:

• Document prior medication trials thoroughly (dates, doses, outcomes, reasons for discontinuation)
• If a prior medication caused an adverse event, document the event and timing
• If a prior medication was contraindicated, document the contraindication
• Some plans allow step therapy override with clinical justification letter
• Appeals on step therapy denials succeed with strong documentation

If you have been managing T2D with diet and exercise alone without medication, expect a metformin trial requirement before insurance approves Mounjaro. The trial may be waived if metformin is contraindicated (severe kidney disease, lactic acidosis history, intolerance).

Cash-pay realities (no LillyDirect for Mounjaro)

Without insurance, brand Mounjaro retails at approximately $1,100 per month in 2026:

• CVS, Walgreens, Walmart: $1,050-$1,150 per month
• Costco, Sam's Club (members): $950-$1,100 per month
• Independent pharmacies: variable
• GoodRx and coupon programs: $1,000-$1,100 per month

Unlike Zepbound, Mounjaro does not have a LillyDirect Self Pay Journey Program. Eli Lilly has chosen to limit its direct-to-consumer cash-pay offering to the obesity indication (Zepbound). Patients with type 2 diabetes who want manufacturer-direct cash-pay pricing currently have no Mounjaro option.

The asymmetry reflects market reasoning: T2D patients more often have insurance coverage with established prior authorization pathways, while the obesity market has more cash-pay demand due to inconsistent coverage. The pattern may shift as Eli Lilly evaluates the LillyDirect performance, but no Mounjaro program exists as of May 2026.

Lilly Cares patient assistance

The Lilly Cares Foundation provides medication at reduced or no cost to qualifying patients:

• U.S. residency required
• Uninsured or with insurance that does not cover the medication
• Income below specific thresholds (typically 400% of federal poverty level, adjusted annually)
• Prescriber signature on application

Application process:

1. Patient and prescriber complete the Lilly Cares application form
2. Submit proof of income, residency, and insurance status
3. Foundation reviews and approves or denies within 1-3 weeks typically
4. If approved, medication ships directly to prescriber's office or patient address
5. Renewal required annually with updated documentation

Lilly Cares is a meaningful option for uninsured patients with documented financial need who do not qualify for Medicaid. The application is paperwork-intensive but the program has helped many patients access medication that would otherwise be out of reach.

The compounded tirzepatide alternative

Compounded tirzepatide is prepared by state-licensed 503A pharmacies in response to individual prescriptions. The October 2024 FDA declaration that the tirzepatide shortage was resolved added restrictions on bulk-quantity compounding.

Compounded tirzepatide path:

1. Enroll through a platform with state-licensed 503A pharmacy partnership
2. Clinician evaluates and documents medical necessity
3. Prescription routes to 503A pharmacy
4. Pharmacy prepares and ships medication
5. Ongoing clinical follow-up

Pricing typically $300-$600 per month. Compounded tirzepatide is not FDA-approved and is not interchangeable with brand Mounjaro or Zepbound. For type 2 diabetes management, the compounded path is less common than for weight loss because insurance coverage of brand Mounjaro is generally better than coverage of brand Zepbound.

Mounjaro vs. Zepbound: which to pursue

The two brands contain identical tirzepatide at identical dosing. Choosing between them depends on:

• Clinical indication: Mounjaro for documented T2D, Zepbound for obesity (BMI 30+ or 27+ with comorbidity) or OSA with obesity
• Insurance coverage: Which one your plan covers under your circumstances
• Cash-pay options: LillyDirect at $349/month for Zepbound vials; no comparable Mounjaro program
• Form factor preference: Mounjaro pen vs. Zepbound pen or vial

Patients with both T2D and obesity often pursue Mounjaro because the diabetes coverage pathway is generally more reliable. Patients with obesity alone pursue Zepbound. Patients with neither indication should not pursue either tirzepatide brand.

Combination therapy with other diabetes medications

Mounjaro is often combined with other T2D medications. Common combinations:

• Mounjaro + metformin: Standard. Complementary mechanisms; no problematic interaction.
• Mounjaro + SGLT2 inhibitor (empagliflozin, dapagliflozin): Permitted; complementary mechanisms.
• Mounjaro + basal insulin: Common. Insulin dose typically reduced 20% when starting tirzepatide to avoid hypoglycemia.
• Mounjaro + sulfonylurea: Possible but requires sulfonylurea dose reduction.
• Mounjaro + DPP-4 inhibitor: Not recommended; discontinue DPP-4 when starting tirzepatide.
• Mounjaro + GLP-1 agonist: Not recommended; discontinue the GLP-1 first.

Insurance prior authorization may require discontinuation of redundant medications (DPP-4 inhibitors, other GLP-1 agonists) before approving Mounjaro.

Common access delays

Missing HbA1c. Insurance requires a recent HbA1c result. If your last lab is older than 90 days, schedule a draw before submitting prior authorization.

Step therapy gaps. If you have not tried metformin, you will likely need to before Mounjaro is approved. If metformin caused side effects, document the issue clearly to avoid having to repeat the trial.

Diagnosis code mismatch. Insurance requires E11.x (type 2 diabetes) for Mounjaro coverage. If your records show prediabetes (R73.x) or another code, the prior authorization will fail.

Pharmacy supply. Mounjaro is generally in stock at major chains, but specific doses may be temporarily unavailable at individual pharmacies. Call ahead or check online inventory.

Refill timing. Insurance plans often have rules about how early refills can be filled. Standard is typically 25-28 days after the prior fill for a 30-day supply.

Contrary view: should weight-loss access be expanded

The diabetes-only restriction on Mounjaro creates inefficiency. Many patients have both T2D and obesity; for them, the brand choice is largely administrative. Some patients have T2D risk factors that don't quite meet diagnostic criteria; they may benefit from earlier tirzepatide initiation that the current label does not support.

Arguments for expanded access:

• Tirzepatide is the same molecule regardless of brand; the label divide is artificial
• Earlier intervention in metabolic syndrome may prevent progression to T2D
• Insurance gating Mounjaro to diabetes while gating Zepbound to obesity creates administrative complexity without clinical benefit

Arguments against:

• FDA approval pathway protects patients by ensuring trial-derived safety data matches the population being treated
• Manufacturer cost and supply considerations require defined indications
• Off-label expansion may dilute the clinical evidence base

The pragmatic position: pursue the brand that matches your clinical indication. Avoid off-label Mounjaro for weight loss when Zepbound exists for that indication.

Decision framework

You have type 2 diabetes and good insurance: Path 1 (insurance). Standard primary care or endocrinology with metformin trial documented.

You have T2D, no insurance, low income: Apply for Lilly Cares patient assistance.

You have T2D, no insurance, above-threshold income: Path 2 (retail cash-pay) or Path 3 (compounded tirzepatide) as a lower-cost alternative.

You have T2D and obesity: Either Mounjaro (diabetes path) or Zepbound (obesity path) can work. Insurance coverage often determines the choice.

You want tirzepatide for weight loss, no diabetes: Pursue Zepbound, not off-label Mounjaro.

You have a boxed-warning contraindication: Not eligible for tirzepatide regardless of brand.

FAQ

How do I get Mounjaro? Insurance with documented T2D (most common), retail cash-pay around $1,100/month, Lilly Cares for qualifying patients, or compounded tirzepatide as an alternative.

Does insurance cover Mounjaro? Yes, generally for documented type 2 diabetes with prior authorization. Often requires metformin trial.

How much does Mounjaro cost without insurance? About $1,100/month at retail. No LillyDirect program exists for Mounjaro.

Can I get Mounjaro for weight loss? Not on label. Zepbound is the FDA-approved tirzepatide for weight loss.

What is Lilly Cares? Eli Lilly's patient assistance program providing medication at reduced or no cost for qualifying low-income uninsured patients.

How long does Mounjaro prior authorization take? 24-72 hours typically; longer if step therapy or additional documentation is required.

What is the difference between Mounjaro and Zepbound? Same active ingredient (tirzepatide), same dosing, different indications. Mounjaro for T2D; Zepbound for obesity and OSA with obesity.

Can I get Mounjaro through telehealth? Yes, with documented T2D and a licensed provider in your state.

Sources

1. FDA. Mounjaro Prescribing Information. Current revision 2025.
2. FDA. Zepbound Prescribing Information. Current revision 2025.
3. American Diabetes Association. Standards of Medical Care in Diabetes, 2025.
4. Eli Lilly. Lilly Cares Foundation: Patient Assistance Program Eligibility and Application. 2025.
5. Eli Lilly. Mounjaro Savings Card: Terms and Eligibility. 2025.
6. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). NEJM. 2021.
7. Centers for Medicare and Medicaid Services. Medicare Part D Coverage of GLP-1 and Combination Agonists. 2025.
8. American Association of Clinical Endocrinologists. Type 2 Diabetes Pharmacotherapy Algorithm. 2024 update.
9. National Council for Prescription Drug Programs. Step Therapy Policy: Position Statement. 2024.
10. State Boards of Pharmacy. 503A Compounding Regulations Survey. NABP, 2025.
11. FDA. Drug Shortages: Tirzepatide Shortage Resolution. October 2024.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with independent licensed clinicians and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. Prescriptions are issued by independent clinicians after clinical evaluation.

Compounded Medication Notice. Compounded tirzepatide is prepared by a state-licensed 503A pharmacy in response to an individual prescription. It is not FDA-approved and is not interchangeable with brand Mounjaro or Zepbound. Formulations vary between compounding pharmacies.

Results Disclaimer. Pricing cited reflects approximate market rates as of May 2026 and may change. Insurance copays vary by plan and patient deductible. Trial outcomes (SURPASS-2) reflect average results in trial populations.

Trademark Notice. Mounjaro, Zepbound, and Lilly Cares are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are trademarks of Novo Nordisk A/S. GoodRx is a registered trademark of GoodRx Holdings. FormBlends is not affiliated with these companies.